Second Clinical Medical College, Lanzhou University, Gansu Province, China;First Aid Center, Lanzhou University Second Hospital, Gansu Province, China;Department of General Surgery, The 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, China.
Intensive Care Unit, Lanzhou University Second Hospital, Gansu Province, China.
Turk J Gastroenterol. 2020 Apr;31(4):331-341. doi: 10.5152/tjg.2020.19341.
BACKGROUND/AIMS: Accumulating evidence reveals esmolol could protect the gut mucosa through the regulation of immune response and inflammation in patients with sepsis. However, its underlying mechanism is not fully understood.
Diamine oxidase (DAO), intestinal fatty acid-binding protein (I-FABP), interleukin (IL)-6, and IL-10 in the plasma of rats were detected by ELISA assay. Western blotting was utilized to measure the expression levels of NF-kappa B-p65, Bcl-2, and cleaved caspase-3 in the intestinal tissues. The survival analysis was performed in each group.
The plasma levels of DAO and IL-10 levels were increased, whereas that of I-FABP and IL-6 were decreased in the sepsis rats after esmolol treatment, indicating that after the esmolol treatment, the intestinal inflammation and damages were remarkably reduced as compared to those in the normal saline treated sepsis rats. NF-κB-p65 and Bcl-2 were highly expressed, but cleaved caspase-3 showed lower expression in the esmolol treated groups. However, at the same time, we observed contrasting results in the normal saline treated group. Western blotting data indicated that the esmolol treatment inhibited the inflammation and apoptosis in the intestinal tissue due to the overexpression of NF-κB-p65 in the celiac sepsis rats. The survival analysis results indicate that the esmolol infusion should be used in the early stages sepsis rats.
Esmolol can suppress inflammation and apoptosis in the intestinal tissue via the overexpression of NF-kappa B-p65 in the early stage sepsis rats. kappa BEarly-stage use of esmolol might be an ideal treatment method for sepsis.
背景/目的：越来越多的证据表明，艾司洛尔可以通过调节脓毒症患者的免疫反应和炎症来保护肠道黏膜。然而，其潜在机制尚不完全清楚。
通过酶联免疫吸附试验检测大鼠血浆中二胺氧化酶（DAO）、肠脂肪酸结合蛋白（I-FABP）、白细胞介素（IL）-6 和 IL-10 的水平。采用 Western blot 法测定肠组织中 NF-κB-p65、Bcl-2 和 cleaved caspase-3 的表达水平。对各组进行生存分析。
与生理盐水处理的脓毒症大鼠相比，艾司洛尔处理后的脓毒症大鼠血浆中 DAO 和 IL-10 水平升高，而 I-FABP 和 IL-6 水平降低，表明艾司洛尔处理后，与生理盐水处理的脓毒症大鼠相比，肠道炎症和损伤明显减轻。NF-κB-p65 和 Bcl-2 表达水平升高，但 cleaved caspase-3 表达水平降低。然而，在生理盐水处理组同时观察到相反的结果。Western blot 数据表明，由于腹腔脓毒症大鼠 NF-κB-p65 的过度表达，艾司洛尔处理抑制了肠道组织的炎症和凋亡。生存分析结果表明，艾司洛尔输注应在早期脓毒症大鼠中使用。
艾司洛尔通过在早期脓毒症大鼠中过度表达 NF-κB-p65，可抑制肠道组织的炎症和凋亡。早期使用艾司洛尔可能是脓毒症的理想治疗方法。
